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ABR

Auditory Brainstem Response

dB (SPL)

decibels (sound pressure level)

Hz

hertz

i.p.

intraperitoneal

KA

kanamycin

kHz

kilohertz

NIHL

noise-induced hearing loss

NIPTS

noise-induced permanent threshold shift

OHC

outer hair cells

SNHL

sensorineural hearing loss
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Introduction
Aminoglycosides are antibiotic drugs used in the treatment of diseases caused by Gramnegative bacteria and tuberculosis. These cost-effective drugs, which include gentamicin,
tobramycin, streptomycin, neomycin, and kanamycin are currently applied clinically most
frequently in underdeveloped countries, and in the most extreme cases of a life-threatening
illness because of their potential ototoxicity. Aminoglycosides are known for causing a loss in
hearing sensitivity, vestibular function, or nephrotoxicity to those who are administered the drug
(Guthrie, 2008). In the inner ear, these drugs target cochlear outer hair cells (OHCs) and type I
vestibular hair cells (Rybak &Whitworth, 2005). This results in a bilateral sensory hearing loss,
mostly affecting high frequencies due to damage of the hair cells in the basal turn of the cochlea
(Guthrie, 2008).

Mouse models in ototoxin research
To gain a better understanding of the cellular mechanisms of aminoglycoside ototoxicity,
it is helpful to study their affects in animal models. Mice, in particular, are increasingly used as a
model of human hearing. The mouse cochlea is anatomically and physiologically similar to that
of a human. Mice also develop and age quickly, making it convenient to study critical and
sensitive periods (Henry & McGinn, 1992). According to Henry (1981), kanamycin's effects are
similar in mice and humans with the majority of hair cell loss being in the basal turn of the
cochlea. The age of the animal, however, greatly influences sensitivity to ototoxic agents. In an
attempt to establish a critical period in mice for kanamycin ototoxicity, Saunders and Chen
(1983) injected C57BL/6 inbred mice with 400 mg/kg, intraperitoneally (i.p.), once daily for four
4
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days in groups aged 6-9, 10-13, or 15-18 days, then sacrificed the mice 15 days post-injection for
morphologic analysis. Animals aged 10 to 13 days showed complete loss of OHCs throughout
the cochlea while mice age 6-9 days only sustained damage to the OHCs in the basal turn.
Different strains of mice have shown different responses to kanamycin treatments. The
CBA/J mouse, in particular, has been shown to have greater threshold shifts after treated with
kanamycin when compared to other strains, such as the C57BL/6 and NKCC1+/- (Chu et al.,
2006). Mice in this study were aged to four weeks in an effort to establish a mouse model of
ototoxicity past the “sensitive” period in developing mice. They received daily kanamycin
injections (700 mg/kg) subcutaneously for 14 consecutive days. Thresholds continued to worsen
3 weeks post treatment (Chu et al., 2006). Wu and colleagues (2001) used the same dosage of
kanamycin as Chen and Saunders (1983) and injected different strains of mice twice daily for 10
consecutive days. They determined that BALBs are affected more sensitive to ototoxicity than
the other strains of mice. It should be noted that a greater dosage was necessary in these animals
because they were considered adult animals. A kanamycin dose of 400 mg/kg i.p. daily for 10
days was shown to produce threshold shift of 60-70 dB in developing mice (Sha et. al, 2001).
Adult animals are able to tolerate higher dosages of kanamycin without experiencing the
same ototoxic effects that occur in their younger counterparts. In a previous study, Henry and
colleagues (1981) compared the affects of kanamycin in mice aged 13, 60, and 380 days. They
received two daily injections of kanamycin (500 mg/kg, i.p.) for two weeks. Auditory function
was assessed two days post treatment with electrocochleograms. Results showed that the preweanling mice had dramatic threshold shifts across all frequencies, while the older two groups of
mice only had shifts in the mid- and high frequencies (Henry et al., 1981). Histological analysis
5
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revealed an extensive OHC loss across the cochlea, while older mice only showed loss of OHCs
in the basal turn. The histological findings supported the electrocochleographic changes after
kanamycin.

Early window of heightened noise vulnerability
The pattern of cochlear damage caused by noise-induced hearing loss is also quite similar
in mice and humans. Cochlear noise injury is manifested as sensorineural hearing loss (SNHL),
mostly affecting the higher frequencies. Like ototoxicity, the consequences of noise exposure are
age dependent. An early study by Henry (1983) looked at the susceptibility of CBA/J mice to
NIHL throughout their life span. Mice were exposed to 124, 114, or 104 dB SPL of octave-band
(12 to 24 kHz) noise for 5 minutes. It was concluded that susceptibility in mice is greatest in a
developmental window extending from 16-90 days of age. Ohlemiller, Wright, and Heidbreder
(2000) applied a noise dose response paradigm to young and old CBA/CaJ, C57BL/6J and
BALB/J mice. In that study, young (1-2 months old) and old (5-7 months old) mice were
exposed to 110 dB of 4 to 45 kHz noise for varying durations. Results confirmed that the
younger mice are indeed more susceptible to noise. Young CBA/CaJ mice, for example, had a
NIPTS after a mere 3.42 minutes of noise exposure, while the older CBA/CaJs required roughly
63 minutes to create the same probability of permanent threshold shifts.

Interactions of simultaneous aminoglycosides and noise
Since the cellular targets of noise and ototoxic drugs are largely the same, it might be
expected that their combination would exacerbate hearing loss. This has been demonstrated in
6

Rice
both animals and humans (Dayal et al., 1971; Quante, 1973; Dayal & Barek, 1975; Marques et
al., 1975; Hawkins et al., 1975; Ryan & Bone, 1978; Brown et al., 1980 (as cited in Humes,
1984); Brummett, Fox, & Kempton, 1992). Gannon, Tso, and Chung (1979) examined the effect
that impulse noise had on guinea pigs that had received a minimal dose of kanamycin (15 mg/kg
vs. 50 mg/kg) and concluded that even when kanamycin alone does not cause any noticeable
damage to hair cells, it can increase hair cells susceptibility to noise injury. Brummett and
colleagues (Brummett, Fox, & Kempton, 1992) injected guinea pigs with subclinical doses of
kanamycin and exposed them to 45, 75, 95, or 115 dBA of noise for 7 days. Again it was
concluded that subclinical doses of kanamycin paired even with normally harmless levels of
noise can cause permanent cochlear damage. Most of these studies used guinea pigs or
chinchillas as the animal model.
Recent experiments in young mice, however, have uncovered a protective effect of subclinical doses of kanamycin (300 mg/kg) against NIHL. In a recent study CBA/J mice 20 days
old were injected every 12 hours for 10 consecutive days, then on day 11 were noise exposed to
30 s of 110 dB SPL broad band noise. While ABRs conducted 10 days post exposure showed
substantial threshold shifts (~50 dB) in saline-treated control mice, the experimental mice (both
noise and kanamycin) showed statistically normal thresholds (Baum, 2008).

Purpose of the present study
This novel finding created the need to determine the minimal amount of kanamycin that
can be administered and still protect from noise injury. Since there is little to no concurring
evidence of an ototoxic drug being used in protection from noise-injury, there is a great need for
7
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understanding this phenomenon. The boundaries of this particular event must be defined. How
few kanamycin doses can be given and still prevent NIHL? The purpose of this study was to
find just how infrequent injections of kanamycin can be administered and protection from noise
exposure is still evident. This was done by injecting kanamycin in young CBA/J mice at
varying intervals (once daily, once every other day, and once every third day) for a span of 10
days.

MATERIALS AND METHODS
Animals
A total of 24 CBA/J mice of either gender were used in this study. All mice were housed
in the Mechanisms of Cochlear Injury Laboratory at Washington University School of Medicine
for 10 days while receiving treatment, and for the remainder of time were housed in the Central
Institute for the Deaf Animal Colony. All procedures were approved by the Animal Studies
Committee at Washington University School of Medicine. Animals were inspected for signs of
otitis media. Any animals with middle ear infection were excluded from the data analysis.

Kanamycin
Mice were assigned to one of seven different treatment groups: kanamycin daily only,
saline daily plus noise, kanamycin daily plus noise, kanamycin daily plus longer duration of
noise, saline daily plus longer duration of noise, kanamycin every other day plus noise, and
kanamycin every third day plus noise (see Table 1 below). Mice that received kanamycin were
injected subcutaneously with a 0.9% commercial saline solution containing 63.93 mg/ml of
8
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kanamycin to yield 300 mg/kg per dose. Injections were given between the hours of 7-9 AM.
No mice died as result of the drug treatment.
Treatment Group

Number of Animals

Kanamycin 1/day (no noise)

2

Saline 1/day + 30 s noise

4

Kanamycin 1/day + 30 s noise

6

Kanamycin every other day + 30 s
noise

6

Kanamycin every 3rd day + 30 s noise

3

Saline 1/day + 1.88 min noise

1

Kanamycin 1/day + 1.88 min noise

2

Table 1: Number of animals per treatment group

Noise Exposure
The majority of the mice assigned to a noise treatment group were exposed to 30 seconds
of 110 dB SPL broadband noise (4-45 kHz). This level and duration is the result of early noisedosing results in the previous study. In keeping with prior studies, the initial hypothesis in the
foundational study Baum (2008) was that subclinical kanamycin would act synergistically to
produce substantial injury. Thus the goal was to identify noise exposure durations (while fixing
overall intensity) that produced little or no NIPTS. Pilot exposures in young CBA/J, however,
showed that exposures as brief as 0.5 minutes resulted in 100% of the mice exhibiting severe
hearing loss. An exposure duration of 4.0 min was originally selected for that study based upon
research conducted by Ohlemiller, Wright and Heidbreder (2000). That study showed that 3.42
9
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minutes was sufficient enough in causing a NIPTS in 6 week old CBA/CaJ mice. Because of the
dramatic hearing loss created in pilot experiments, it was determined that a noise-dose response
experiment needed to be conduced. Rice, Gagnon, and Ohlemiller (2009) compared 6 week-old
CBA/J and CBA/CaJ mice to find the
threshold of duration in which NIPTS
would be seen for each strain
separately. The conclusions of this
study were that 0.90 minutes of noise
was sufficient enough to cause 90% of
the young CBA/Js to have a NIPTS,
while 4.05 minutes was the length of
duration that caused a similar loss in
the CBA/CaJs. It was decided that for
this study, 30 seconds of noise would
be reliably produce a NIPTS in young

Figure 1: The proportion of young CBA/J and
CBA/CaJ mice meeting the criterion for NIPTS. The
minimum NIPTS exposure for CBA/J (0.9 min) was
clearly different from that in CBA/CaJ (4.05 min)
Reprinted with permission from
Rice, Gagnon, and Ohlemiller, 2009

CBA/J mice. It should be noted that

this duration of noise produces more hearing loss in 30 day old CBA/J mice than suggested by
Figure 1, presumably because the extent of noise vulnerability decreases between 30 days and 6
wks of age.
Mice were placed in groups of two in a 21x21x11 cm wire cage surrounded by four
speakers set at 0, 90, 180, and 360 degrees azimuth. This apparatus was housed within a singlewalled, foam-treated sound booth. In order to ensure uniform exposure, the cage was rotated at
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0.013 Hz throughout the exposure duration. The noise was generated using General Radio
1310 generators and filtered with Krohn-Hite 3550 filters. Food and water were not accessible
during the time of exposure. Mice in a noise treatment group were exposed 15 minutes after
final injections. The rationale for this was previous evidence indicating that peak serum levels
are reached approximately 15 minutes after administering kanamycin (cited in Wu et al., 2001).

ABR Recordings
Auditory brainstem recordings were obtained ten days post treatment, or approximately
40 days post gestation. Animals in the kanamycin only group (no noise exposure) underwent
ABR testing at 15 minutes post injection on day 10 (that is, at the time when noise exposure
would occur), as well as 40 days post gestation. Animals were anesthetized using a ketamine and
xylazine solution (80/15 mg/kg, i.p). Subdermal needle electrodes were placed in the vertex,
back, and behind the right pinna. The animal's body temperature was kept at a constant 37.0 °C
through the use of an isothermal pad and monitored via rectal probe. Mice were positioned with
their head's placed 7 cm from the speaker. The base of the left ear was clamped with a small clip
so that only the right side was stimulated. Stimuli were presented 1000 times through the right
speaker in 5 millisecond tonebursts at the following frequencies: 5, 10, 20, 28.3, and 40 kHz.
Stimulus presentation and data acquisition utilized Tucker Davis Technologies System II
hardware and software (BioSig 32). Thresholds were defined as the lowest sound level (varied
in 5 dB steps) that produced Wave I of the ABR.
After ABR thresholds were obtained for each frequency, mice were overdosed using
sodium pentobarbital (60 mg/kg i.p.) and transcardially perfused with 2.0% paraformaldehide
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solution. The cochleae were harvested and placed in fixative. Cochleae were later decalcified
using an EDTA sodium solution, stained with Osmium, dehydrated using Acetone, and finally
embedded in Epon-Araldite.

RESULTS
A two-way analysis of variance (ANOVA) was performed to in order to determine if there
was any statistical significance in threshold differences between groups. Among the seven
different treatment groups, only two were
found to have statistically significant
differences in thresholds. There was a
clear difference between the ABR
thresholds in animals who received
kanamycin daily and 30 seconds of noise
and those animals that received the same
dosage of saline daily and noise (Figure 2).

Figure 2: Average thresholds for saline 1/day +
30 s noise and kanamycin 1/day + 30 s noise

Animals that received saline daily for 10
days had thresholds that were 30 to 40 dB greater than those animals in the kanamycin daily
group.
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Animals who received
kanamycin every other day also showed
statistically different thresholds when
compared to the saline daily + noise
group (Figure 3). Majority of those
within the kanamycin every other day
group saw at least partial, if not
complete, protection from 30

Figure 3: Saline 1/day + 30 s noise, KA every other day
+ 30 s noise

seconds of noise. There was little
variation in between thresholds at all frequencies in all of the groups that received doses of
kanamycin. Animals that were injected daily with kanamycin and not exposed to noise showed
no threshold shifts across all tested frequencies when compared to previous thresholds obtained
at 30 days post-gestation directly following drug treatment.
There were two animals who received daily injections of kanamycin for 10 days then
were exposed to noise for 1.88 min. One of the animals showed complete protection from even
this duration of noise, while the other had substantially elevated thresholds. A larger number
would help determine the effectiveness of protection that kanamycin has for longer durations of
noise exposures.

DISCUSSION
The purpose of this study was to determine the minimum applications of kanamycin that
can protect young CBA/J mice from NIHL. The findings of this study help confirm surprising
13
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interactions previously reported. Baum (2008) concluded that mice receiving twice daily doses
of kanamycin plus noise exposure showed no significant average shifts in threshold compared to
control groups. The present results argue for the existence of a robust and easily established
‘protected state’, such that even injections of kanamycin given every third day for ten days are
sufficient to protect from NIHL.

Subclinical kanamycin as a preconditioning stressor
Threshold preservation against noise by kanamycin may represent a form of
preconditioning. Preconditioning, as defined by Gagnon and colleagues (2007), refers to “the
ability of a non-damaging or minimally damaging stressor to confer protection against the effects
of a later and more injurious stressor”. These investigators found that hypoxia prevents the
exacerbation of NIHL in CBA mice when exposed to 90 minutes of broadband noise. Yoshida
and colleagues (1999) determined that heat stress preconditioning can also protect mice from
NIHL. An increase in heat shock proteins within the CBA/CaJ mouse cochlea created protection
from 100 dB of octave band noise. Other cellular processes that may underlie preconditioning
are increased levels of glucocorticoid stress hormones and improved blood flow (Wang &
Liberman, 2002).
It is possible that the stress of handling mice alone is somewhat protective against noise
exposure. That is why one treatment group received saline daily prior to noise exposure. Since
the mice in that group had significant threshold shifts this factor could be ruled out in our results.
Also, we included a treatment group that received only kanamycin daily with no noise exposure.
Animals in that group showed no threshold shifts due to kanamycin alone, therefore this dose of
14
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kanamycin does not cause any hearing loss after 10 consecutive days of administration. More
recent findings have shown that a single dose of kanamycin, when administered 15 minutes prior
to noise, is not enough to protect from NIHL (Baum, 2008). These findings imply that the mere
presence of kanamycin is not adequate to mediate protection. Chronic treatment with kanamycin
may be required to up-regulate protective mechanisms in the cochlea that prevent NIHL. The
minimum number of kanamycin injections that is protective was not addressed in this present
study.
There is little support of the protective nature of aminoglycosides in preventing NIHL in
the literature. This could be due to the fact that most of the studies that looked at the synergistic
effects between kanamycin and noise were done with adult animals. The protection may be seen
only in the mouse and not in guinea pigs or chinchillas, which were the model of animals utilized
in majority previous studies. Doses of kanamycin also varied widely among these studies as well.

Clinical implications and future experiments
This study confirms the previous finding that kanamycin, when paired with noise in
young CBA/J mice, can protect against NIHL Identification of ‘boundary conditions’ for
establishing the postulated protected state is important, as it should promote the discovery of the
underlying cellular mechanisms. Surprisingly, the present experiments actually produced little
evidence of limits to the protection afforded by kanamycin. More experimental conditions must
therefore be tested. Among the remaining unknowns is the question of how much noise can be
protected against. One group in the present study indicated that protection by kanamycin is not
limited to 30 s exposures. However, this group contained two animals, which is not a large
15
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enough sample to determine the effectiveness of kanamycin protection.
Further studies should address the generality of the present results both with regard to
mouse strain and type of ototoxin that can elicit protection. That young CBA/J mice are
somehow unique in this regard cannot be ruled out, given the evidence presented here that these
mice are phenomenally vulnerable to noise. Investigations of this type may help establish
whether there are specific genes that determine whether kanamycin protects–or worsens-noise
injury in any individual.
It is truly paradoxical that a compound widely agreed to be highly toxic the inner ear as
kanamycin can be protective. The findings of this study bring about the possibility of using
pharmaceuticals in the prevention of auditory damage. There is a great need to find protective
agents for those individuals who are exposed to recreational and occupational noise. It is
important to find the underlying protective mechanisms that kanamycin induces to prevent
NIHL. Further more, if the mechanisms of protection induced by kanamycin are discovered,
alternative ways of up-regulating these pathways could be used to prevent cochlear damage and
hearing loss from noise.
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APPENDIX A: Mean thresholds by treatment group
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APPENDIX B: Daily Injections/Body Weight Data Form
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APPENDIX C: ABR Data Log Form
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